Microbiological basis for economical outpatient antibacterial treatment of community acquired pneumonia
Abstract
Based on the antibacterial sensitivity of community-acquired pneumonia pathogens expenses for antimicrobial medication were prognosed. The expenses for the treatment of 100 patients were calculated according to the first-line antibiotics (ampicillin, azithromycin, or cefuroxime sodium) cost required for the treatment course of all the patients and those of second-line antibiotics for the patients whose pathogens were tolerant to the first drug. Ciprofloxacin was proposed as the second-line antibiotic. 58% of pathogens were sensitive to ampicillin and 71% and 85% of them were sensitive to azithromycin and cefuroxime correspondingly. We also investigated community-acquired pneumonia pathogens sensitivity to non-antihaemophylic macrolides but so long as it did not exceed 48% the further assessment of these drugs cost was not performed. The antibiotics expenditures were minimal when the first-line drug was Sumamed (azithromycin); they were greater for ampicillin and maximal for Zinnat (cefuroxime sodium). Thus, according to the data obtained Sumamed's efficacy and cost is thought to be optimal first-line antibiotic for the treatment of community-acquired pneumonia.
About the Authors
M. B. Bogdanov
Медико-санитарная часть №1 АМО ЗИЛ
Russian Federation
Russian Federation
T. V. Chernenkaya
Медико-санитарная часть №1 АМО ЗИЛ
Russian Federation
Russian Federation
References
1. Антибактериальная терапия пневмоний у взрослых: Учебнометод. рекомендации.- М.. 1998.
2. Белоусов Ю.Б., Шмат С.С., Селевина Т.Г., Ефременкова О.В. Фармакоэкономика лечения инфекций нижних дыхательных путей в амбулаторных условиях / / Пульмонология.- 2000.- № 3 - С.77-79.
3. Богданов М.Б., Чёрненькая Т.В. Влияние антибиотического анамнеза на этиологию внебольничных пневмоний / / Клин, фармакол. и тер.- 1999.- Т.8, № 5.- С.20-22.
4. Федеральное руководство для врачей по использованию лекарственных средств.- М., 2000.- Вып.1.
5. Bartlett J.G., Breirnan R.F., Mandell L.A. et al. Guidelines from the infectious diseases society of America. Communityacquired pneumonia in adults: guidelines for management / / Clin. Infect. Dis.- 1998 - Vol.26 - P.811-838.
6. Bergey’s Manual of Systematic Bacteriology.- Baltimore; London, 1989.
7. Felmingham D., Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992.- 1996 / / J. Chemother.- 1999.- V o l.ll.- Suppl.l - P.5-21.
8. Fluit A.C., Schmitz F.J., Jones M.F. et al. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: First results from the SEN T R Y Antimicrobial Surveillance Program 1997 / / Int. J. Infect. Dis.- 1999.- Vol.3, № 3.- P. 153-156.
9. Huchon G., Woodhead М ., Gialdroni-Grassi G. et al. Guidelines for management of adult community-acquired lower respiratory tract infections / / Eur. Respir. J.- 1998.- Vol.11.- P.986-991.
10. Isenberg H.D. Clinical Microbiology. Procedures Handbook.- Washington: ASM , 1992.
11. Lieberman D., Shvartzman P., Lieberman D. et al. Etiology of respiratory tract infection in adults in a general practice setting / / Eur. J. Clin. Microbiol. Infect. Dis.- 1998.- Vol. 17, № 10.- P.685-689.
12. Prontani D., Washton H., Bouchillon S., Johnson J. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin / / Ibid.- № 6 - P.413-419.
Review
For citations:
Bogdanov M.B., Chernenkaya T.V. Microbiological basis for economical outpatient antibacterial treatment of community acquired pneumonia. PULMONOLOGIYA. 2000;(4):73-78. (In Russ.)
Views:
185
Email this article 